NIH Initiative Aims to Improve Immunotherapy.
The NIH has launched a new collaboration with 11 biopharmaceutical companies and four academic cancer centers to identify the most effective biomarkers for immunotherapy. The public-private partnership will analyze patient samples from clinical trials and aims to develop a standard panel of biomarkers to determine which patients are likely to benefit from immunotherapy and to track their responses.